Neck News and Research

RSS

Cancer vaccines receive orphan drug designation for advanced head and neck cancer

Two experimental vaccines from the University of Maryland, Baltimore (UMB) recently received a federal orphan drug designation for advanced head and neck cancer, according to a company official.

9 Apr 2009

Experimental vaccine shows promise for the treatment of early lung cancer

An experimental vaccine that triggers the patient's immune system to identify and attack specific tumor cells is showing new promise for the treatment of early lung cancer.

6 Apr 2009

Zosano Pharma presents positive results for needle-free osteoporosis therapy

Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, has presented positive results from its phase 2 study of the ZP-PTH rapid delivery patch for the treatment of osteoporosis at the 8th International Symposium on Osteoporosis in Washington, D.C.

6 Apr 2009

Monoclonal antibody cancer therapy

The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects.

6 Apr 2009

New 90-second radiotherapy therapy called RapidArc

The University of Alabama at Birmingham (UAB) this month became the first U.S. medical center to offer a speedier cancer radiation therapy.

5 Apr 2009

Discovery of marker for severity in adult brain cancer

Researchers at UT Southwestern Medical Center have identified a new biological indicator that may help identify which brain-cancer patients have the most aggressive forms of the disease.

1 Apr 2009

Diet and lifestyle choices influence cancer survival

Head and neck cancer patients who smoked, drank, didn't exercise or didn't eat enough fruit when they were diagnosed had worse survival outcomes than those with better health habits, according to a new study from the University of Michigan Comprehensive Cancer Center.

1 Apr 2009

Childhood hearing loss more prevalent among Hispanic-American, low-income households

A new review of medical databases shows that neonatal hearing loss, already one of the most common birth disorders in the United States, is especially prevalent among Hispanic-Americans and those from low-income households, according to the April 2009 issue of Otolaryngology-Head and Neck Surgery.

1 Apr 2009

New streamlined triage system for "brain attack"

Taking a page out of the playbook developed by cardiologists nearly two decades ago to promote the warning signs and swift treatment for heart attacks, a multidisciplinary team of stroke experts at the University of Rochester Medical Center (URMC) have created a new streamlined triage system at Strong Memorial Hospital's Emergency Department (ED) to provide rapid evaluation and specialized treatments to "brain attack," or stroke, patients.

1 Apr 2009

Improving cancer therapy achieved through taste, odor intervention

Cancer and its therapies, including chemotherapy and radiotherapy, may directly alter and damage taste and odor perception, possibly leading to patient malnutrition, and in severe cases, significant morbidity, according to a Virginia Tech - Wake Forest University Comprehensive Cancer Center compilation of various existing studies.

30 Mar 2009

FDA approves IXIARO for Japanese encephalitis

The U.S. Food and Drug Administration has approved IXIARO, a vaccine to prevent Japanese encephalitis (JE) which is caused by a mosquito-transmitted virus found mainly in Asia. IXIARO will be the only vaccine for JE available in the United States.

30 Mar 2009

High dosage brachytherapy obtains excellent results in head and neck tumors

High-dosage perioperative brachytherapy (applied within the surgical process) obtains excellent results in the treatment of head and neck tumours, at the same time as reducing the period of radiation.

29 Mar 2009

3-drug chemotherapy combo increases organ preservation in patients with larynx cancer

Patients with larynx cancer who received a three-drug combination of docetaxel, cisplatin and 5-fluorouracil (TPF) during induction chemotherapy were more likely to retain larynx function than were patients treated with cisplatin and 5-fluoruracil (PF) alone, according to data from a randomized controlled trial in the March 24 online issue of the Journal of the National Cancer Institute.

24 Mar 2009